Home › NDC Lookup › RxCUI directory › RxCUI 1940709

Glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet [Mavyret] — RxCUI 1940709

Name: Glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet [Mavyret] (RxCUI 1940709)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1940709 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1940709

Official nameGlecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet [Mavyret]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asMavyret 100 MG / 40 MG Oral Tablet

FDA products mapped2

Package NDCs mapped5

Reported Medicaid activity (SDUD)44,772 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Glecaprevir and Pibrentasvir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

For most patients who have never been treated before, Mavyret is taken for just 8 weeks — which is shorter than many older hepatitis C treatments. If you've been treated before or...
How long do I have to take Mavyret, and will it actually cure my hepatitis C?
Yes, and this one really matters. Food — even a moderate-fat meal — significantly increases how much of both medicines gets absorbed into your bloodstream. Taking Mavyret on an emp...
Do I really need to take it with food every single day?

📖 Read our full Glecaprevir and Pibrentasvir guide →

🕸️ Concept Web — How Glecaprevir 100 MG / pibrentasvir 40 MG Oral Tab... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet [Mavyret] RxCUI 1940709 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 3

The active substance itself — no strength, form, or brand attached yet.
- Glecaprevir 1940635 IN
- Pibrentasvir 1940636 IN
- Glecaprevir / pibrentasvir 1940702 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Mavyret 1940704 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Glecaprevir / pibrentasvir Oral Tablet 1940701 SCDF
- Glecaprevir / pibrentasvir Oral Product 1940699 SCDG
- Glecaprevir / pibrentasvir Pill 1940700 SCDG
- Glecaprevir / pibrentasvir Oral Tablet [Mavyret] 1940706 SBDF
- Mavyret Oral Product 1940707 SBDG
- Mavyret Pill 1940708 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet 1940703 SCD
- Glecaprevir 100 MG 1940697 SCDC
- Pibrentasvir 40 MG 1940698 SCDC
- Glecaprevir 100 MG / pibrentasvir 40 MG [Mavyret] 1940705 SBDC

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet SCD · 1940703
Glecaprevir 100 MG SCDC · 1940697
Pibrentasvir 40 MG SCDC · 1940698
Glecaprevir / pibrentasvir Oral Tablet SCDF · 1940701
Glecaprevir / pibrentasvir Oral Product SCDG · 1940699
Glecaprevir / pibrentasvir Pill SCDG · 1940700

Brand-Name Concepts

Glecaprevir 100 MG / pibrentasvir 40 MG [Mavyret] SBDC · 1940705
Glecaprevir / pibrentasvir Oral Tablet [Mavyret] SBDF · 1940706
Mavyret Oral Product SBDG · 1940707
Mavyret Pill SBDG · 1940708
Mavyret BN · 1940704

📦 FDA Products & Package NDCs

2 products · 5 package NDCs

5 package NDCs map to RxCUI 1940709 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00074-2600-28	1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET	Mavyret	AbbVie Inc.	2021-06-22
00074-2625-04	4 CARTON in 1 CARTON (0074-2625-04) / 7 BLISTER PACK in 1 C...	Mavyret	AbbVie Inc.	2025-04-15
00074-2625-28	4 CARTON in 1 CARTON (0074-2625-28) / 7 DOSE PACK in 1 CART...	Mavyret	AbbVie Inc.	2017-08-03
00074-2625-56	2 CARTON in 1 CARTON (0074-2625-56) / 4 CARTON in 1 CARTON...	Mavyret	AbbVie Inc.	2017-08-03
00074-2625-84	84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-84)	Mavyret	AbbVie Inc.	2021-06-22

Observed labelers: AbbVie Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.